Quick Answer
ORAMED PHARMACEUTICALS INC. reported Cash and Equivalents of $45.95 million for fiscal year 2025.
ORAMED PHARMACEUTICALS INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $45.95M | -15.6% |
| 2024 | $54.42M | +501.0% |
| 2023 | $9.05M | -77.6% |
| 2022 | $40.46M | -47.6% |
| 2021 | $77.25M | +300.3% |
| 2020 | $19.30M | +479.6% |
| 2019 | $3.33M | -33.4% |
| 2018 | $5.00M | +25.9% |
| 2017 | $3.97M | +1.6% |
| 2016 | $3.91M | +21.6% |
| 2015 | $3.21M | +82.3% |
| 2014 | $1.76M | -22.4% |
| 2013 | $2.27M | -48.7% |
| 2012 | $4.43M | +192.9% |
| 2011 | $1.51M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $52.18M | — | +230.3% |
| June 30, 2025 | $15.80M | — | -71.0% |
| December 31, 2024 | $54.42M | +501.0% | +193.0% |
| March 31, 2024 | $18.58M | — | +105.1% |
| December 31, 2023 | $9.05M | — | -71.6% |
| November 30, 2021 | $31.88M | +113.5% | -58.7% |
| August 31, 2021 | $77.25M | +300.3% | +34.5% |
| May 31, 2021 | $57.41M | +516.5% | +69.8% |
- ORAMED PHARMACEUTICALS INC. showed a decrease of -15.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2011–2025 period, ORAMED PHARMACEUTICALS INC.’s cash and equivalents has grown by 2936.8% (from $1.51 million to $45.95 million).
- The most recent figure is from ORAMED PHARMACEUTICALS INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: